$ADIL News

Last published 6d ago

6d agoADIL AZRAzora Therapeutics Appoints Board of Directors with Extensive Drug Development and Inflammatory Bowel Disease ExpertiseGlobeNewswireLOS ANGELES, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Azora Therapeutics, Inc. (NASDAQ:AZR), a biopharmaceutical company developing treatments for serious inflammatory diseases, today announced it has established a
2w agoADILAdial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative ColitisGlobeNewswireStockholders approved the conversion of the preferred stock issued in the June 2026 acquisition of Azora Therapeutics Azora’s common stock to begin trading on Nasdaq under the ticker symbol "AZR" New
2w agoADILAdial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial OfficerGlobeNewswireSeasoned public company CFO with deep autoimmune disease experience has helped raise more than $1 billion over a 20+ year biotech career Will lead the Company’s finance organization and capital strategy as it
3w agoADILAdial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative ColitisGlobeNewswireFormer Dermavant Chief Scientific Officer led development of tapinarof, the first FDA-approved AhR agonist, from mechanistic understanding through approval and commercialization Will lead AT177 through IND-enabling
2mo agoADILAdial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireGLEN ALLEN, Va., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company") today announced that the Company’s Compensation Committee has granted a new
2mo agoADILAdial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business UpdateGlobeNewswireCompleted acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor ("Ahr") agonist in development for ulcerative colitis, to its pipeline Closed
4mo agoADILAdial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE FinancingGlobeNewswireGLEN ALLEN, Va., June 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company") today announced that the Company's Compensation Committee and Board of Directors granted Matthew
5mo agoADILAdial Pharmaceuticals Acquisition of Azora Therapeutics - Adial PharmaceuticalsEarnings Call TranscriptsGreetings. Welcome to ADIL Pharmaceuticals' acquisition of Azora Therapeutics Conference Call. At this time, all participants are in a listen-only mode. If anyone should require operator assistance during the conference,
5mo agoADILAdial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million FinancingGlobeNewswire- Acquisition of Azora and concurrent private placement positions the combined company to advance its pipeline through key clinical milestones in ulcerative colitis, including Phase 1 initiation in mid-2027 - Azora's
6mo agoADILAdial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business UpdateGlobeNewswireGLEN ALLEN, Va., May 11, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
6mo agoADILAdial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045GlobeNewswireGLEN ALLEN, Va., April 29, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
6mo agoADILAdial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development ProgramGlobeNewswireGLEN ALLEN, Va., April 27, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
6mo agoADILAdial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 TrialGlobeNewswireGLEN ALLEN, Va., April 22, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
7mo agoADILAdial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for VeteransGlobeNewswireGLEN ALLEN, Va., March 24, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of treatments for
8mo agoADILAdial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business UpdateGlobeNewswireGLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment
8mo agoADILAdial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive AgreementGlobeNewswireGLEN ALLEN, Va., March 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of treatments for
8mo agoADILAdial Pharmaceuticals Regains Full Compliance with Nasdaq Listing RequirementGlobeNewswireGLEN ALLEN, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
8mo agoADILAdial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to OneGlobeNewswireGLEN ALLEN, Va., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
8mo agoADILAdial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswireGLEN ALLEN, Va., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
9mo agoADILAdial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04GlobeNewswireGLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
9mo agoADILAdial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price RequirementGlobeNewswireGLEN ALLEN, Va., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
10mo agoADILAdial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045GlobeNewswireGLEN ALLEN, Va., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
11mo agoADILAdial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross ProceedsGlobeNewswireGLEN ALLEN, Va., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
12mo agoADILAdial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireGLEN ALLEN, Va., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
1y agoADILAdial Pharmaceuticals CEO was a Featured Guest on The Big Biz ShowGlobeNewswireGLEN ALLEN, Va., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
1y agoADILAdial Pharmaceuticals Partners with Genomind for Precision Medicine Testing SolutionGlobeNewswireGLEN ALLEN, Va., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
1y agoADILAdial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04GlobeNewswireGLEN ALLEN, Va., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
1y agoADILAdial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price RuleGlobeNewswireGLEN ALLEN, Va., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
1y agoADILAdial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder TreatmentsGlobeNewswireGLEN ALLEN, Va., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
1y agoADILAdial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireGLEN ALLEN, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
1y agoADILAdial Pharmaceuticals Completes Successful EOP2 FDA MeetingGlobeNewswireMeeting Completion Marks Major Step Toward Phase 3 AD04 Trial Launch Strategic Partnership Discussions Expected Following the Positive FDA Meeting GLEN ALLEN, Va., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adial
1y agoADILAdial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing RequirementGlobeNewswireGLEN ALLEN, Va., July 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
1y agoADILAdial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product SupplyGlobeNewswireScope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File Scope Of Agreement With Thermo Fisher to Provide Manufacturing Services Including Demonstration, Clinical,
1y agoADILAdial Pharmaceuticals Announces Pricing of $3.6 Million Public OfferingGlobeNewswireGLEN ALLEN, Va., June 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
1y agoADILAdial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA MeetingGlobeNewswireEnd of Phase 2 Meeting has been Rescheduled for July 29th Meeting to Discuss Upcoming Clinical Development Plan and Protocol Designs Strategic Partnership Discussions Expected to Accelerate Following a Positive FDA
1y agoADILAdial Pharmaceuticals Advances Toward Phase 3 Development for AD04GlobeNewswireGLEN ALLEN, Va., June 11, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing precision treatments for
1y agoADILAdial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireGLEN ALLEN, Va., May 15, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
1y agoADILAdial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 StudyGlobeNewswireGlen Allen, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
1y agoADILAdial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug AdministrationGlobeNewswireMeeting to Take Place on July 25, 2025 Meeting's Purpose is To Discuss Upcoming Clinical Development Plan and Protocol Designs GLEN ALLEN, Va., May 08, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc.
1y agoADILAdial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross ProceedsGlobeNewswireGLEN ALLEN, Va., May 02, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
1y agoADILAdial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use DisordersGlobeNewswireGLEN ALLEN, Va., May 01, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
1y agoADILAdial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business UpdateGlobeNewswireGLEN ALLEN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
1y agoADILAdial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04GlobeNewswireFDA feedback confirms Adial's proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the 505(b)(2) regulatory registration pathway for approval Adial moves forward with
1y agoADILAdial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug DependenciesGlobeNewswireNew Patent covers claims which focus on method for identifying genetic markers in patients with alcohol or opioid related disorders Patent expands the identification of potential treatment candidates for AD04
1y agoADILAdial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related DisordersGlobeNewswireGLEN ALLEN, Va., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
1y agoADILAdial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use DisorderGlobeNewswireCompletion enables the End-of-Phase 2 (EOP2) interaction with the FDA on the design of the Phase 3 program and is expected to facilitate ongoing partnership discussions Adial's formulation exhibited predictable
1y agoADILAdial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype CombinationsGlobeNewswireGLEN ALLEN, Va., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
1y agoADILAdial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use DisorderGlobeNewswireConfirmed relative bioavailability to the reference standard, dose proportional increases in pharmacokinetic exposure, and no food effect Marks final study needed for the upcoming FDA meeting for the Phase 3 study
1y agoADILAdial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswireGLEN ALLEN, Va., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
2y agoADIL VRPXAdial Pharmaceuticals Appoints Vinay Shah as Chief Financial OfficerGlobeNewswireGLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and